The purpose of the study is to evaluate the plasma drug concentrations of three formulations of PF-05190457 after administration of single doses to healthy volunteers.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Enrollment
16
100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state
100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fasted state
100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fasted state
Pfizer Investigational Site
Singapore, Singapore
The single dose pharmacokinetics of PF-05190457 in three formulations will be described by estimating parameters of Area Under the Curve (AUC) and its ratio between formulations as data permit.
Time frame: 0 - 48 hours post dose
The single dose pharmacokinetics of PF-05190457 in three formulations will be described by estimating parameters of Maximum Concentration (Cmax) and its ratio between formulations as data permit.
Time frame: 0 - 48 hours post dose
The single dose pharmacokinetics of PF-05190457 in three formulations will be described by estimating parameter of Time of Maximum concentration (Tmax) as data permit.
Time frame: 0 - 48 hours post dose
The single dose pharmacokinetics of PF-05190457 in three formulations will be described by estimating parameter of Elimination of half-life (t ½ ) as data permit.
Time frame: 0 - 48 hours post dose
The ratio of fasted to fed single dose pharmacokinetics of PF-05190457 in two test formulations will be described by estimating parameters of Area Under the Curve (AUC) and its ratio between fed states as data permit.
Time frame: 0 - 48 hours post dose
The ratio of fasted to fed single dose pharmacokinetics of PF-05190457 in two test formulations will be described by estimating parameters of Maximum Concentration (Cmax) and its ratio between fed states as data permit.
Time frame: 0 - 48 hours post dose
Changes in plasma glucose and insulin due to single doses of three formulations of PF-05190457 will be estimated.
Time frame: 0 - 24 hours post dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fed state
100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state
100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fasted state
100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fasted state
100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fed state